BioCentury | Apr 16, 2021
Targets & Mechanisms

New targets featured at AACR signal growing opportunity in established mechanisms

The bulk of the new targets presented at AACR21 involve pathways and mechanisms active in tumor cells rather than immune cells, reflecting the biotech industry’s growing interest in targeted oncology and...
BioCentury | Apr 9, 2021
Translation in Brief

Two ways to reverse CAR T cell exhaustion; plus a ligand and its receptor in a single vector, Cleave, Amazentis and Cello

A Stanford University team led by Crystal Mackall, co-founder of Lyell Immunopharma Inc. and Obsidian Therapeutics Inc., described in Science two ways to prevent or reverse CAR T cell exhaustion. The first is based on a...
BioCentury | Apr 7, 2021
Distillery Therapeutics

RECK, an inhibitor of amyloid precursor protein cleavage, as a target for Alzheimer’s

DISEASE CATEGORY: Neurology INDICATION: Alzheimer’s disease Blocking RECK, a membrane-tethered inhibitor of APP-cleaving enzyme ADAM10, could treat Alzheimer’s disease. Levels of membrane-tethered...
BioCentury | Mar 16, 2021
Product Development

The clinical pipeline for Alzheimer’s disease: Data Byte

Although amyloid-lowering agents still represent the lion’s share of late-stage candidates for Alzheimer’s disease, they account for less than 20% of compounds across all clinical stages. Tau inhibition, modulation of neurotransmitter signaling, and quelling of...
BioCentury | Mar 11, 2021

March 10 Quick Takes: Eddy Wu’s Arctic Vision raises $100M; plus Touchlight, NeoPhore, MediciNova-BARDA and Neurelis

Arctic Vision (Shanghai) Biotechnology Co. Ltd. raised $100 million in a series B round led by Loyal Valley Capital. The funds will go in part to support the company’s trio of late-stage ophthalmology programs and establish...
BioCentury | Mar 9, 2021
Product Development

Palmoplantar pustulosis pipeline: Data Byte

AnaptysBio’s Phase II miss for palmoplantar pustulosis (PPP) may indicate that overactive IL-36 signaling is not the dominant driver of the disease. The news could be a warning for Boehringer Ingelheim GmbH, which has spesolimab (BI...
BioCentury | Feb 2, 2021
Product Development

Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas

Immunovant Inc. (NASDAQ:IMVT) lost 42% to $25.08 on Tuesday after announcing it was pausing trials of anti-FCRN mAb IMVT-1401 (batoclimab) due to elevated total cholesterol and LDL signals in the Phase IIb ASCEND GO-2 thyroid...
BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

Propelled by new insights into disease biology, the clinical pipeline for ALS has grown to at least 43 programs attacking the disease from a dozen different directions. With six of those programs in Phase...
BioCentury | Jan 1, 2021
Product Development

Not done yet. The COVID R&D Alliance has plenty on its plate for 2021

With little fuss or fanfare, the COVID R&D Alliance was created early in the pandemic by the biopharma industry’s biggest players to solve one of the world’s most devastating problems in a century....
BioCentury | Dec 22, 2020

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

Cytokinetics regains European rights from Servier to heart failure programCytokinetics Inc. (NASDAQ:CYTK) regained European rights to heart failure treatment omecamtiv mecarbil from Servier. The deal termination comes a month after Amgen Inc. (NASDAQ:AMGN) returned its...
Items per page:
1 - 10 of 1221